The company highlighted a series of strategic moves during the year, including the acquisition of WOKADINE, marking its entry into the Rs. 648 Cr Povidone Iodine market
Strong export-led growth and improved profitability as the company focuses on CNS drug development and global regulatory footprint
The hospital chain reported strong growth driven by its Gurugram facility, international patient inflow, and operational efficiencies
The biosimilars business generated Rs. 10,431 crore in FY26 revenue, up 16% year-on-year
With robust FY26 growth, plans AI-led diagnostics and genomic testing expansion
FY26 revenue rises 17% to Rs. 5,453 crore as US generics business jumps 49% and adjusted EBITDA margin improves to 26% for the quarter
The company reported robust revenue and profit growth for FY26, supported by strong CDMO performance, improving margins, and expansion across advanced manufacturing platforms
Pharma major reports FY26 revenue of Rs 9,204 crore with 16.6% growth
The private funding rose 38% amid growing international collaborations and CDMO demand
Growth was supported by stronger COVID vaccine sales and expanded government supply agreements in international markets
Subscribe To Our Newsletter & Stay Updated
